Cargando…

Empowering drug off-target discovery with metabolic and structural analysis

Elucidating intracellular drug targets is a difficult problem. While machine learning analysis of omics data has been a promising approach, going from large-scale trends to specific targets remains a challenge. Here, we develop a hierarchic workflow to focus on specific targets based on analysis of...

Descripción completa

Detalles Bibliográficos
Autores principales: Chowdhury, Sourav, Zielinski, Daniel C., Dalldorf, Christopher, Rodrigues, Joao V., Palsson, Bernhard O., Shakhnovich, Eugene I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256842/
https://www.ncbi.nlm.nih.gov/pubmed/37296102
http://dx.doi.org/10.1038/s41467-023-38859-x
_version_ 1785057192447049728
author Chowdhury, Sourav
Zielinski, Daniel C.
Dalldorf, Christopher
Rodrigues, Joao V.
Palsson, Bernhard O.
Shakhnovich, Eugene I.
author_facet Chowdhury, Sourav
Zielinski, Daniel C.
Dalldorf, Christopher
Rodrigues, Joao V.
Palsson, Bernhard O.
Shakhnovich, Eugene I.
author_sort Chowdhury, Sourav
collection PubMed
description Elucidating intracellular drug targets is a difficult problem. While machine learning analysis of omics data has been a promising approach, going from large-scale trends to specific targets remains a challenge. Here, we develop a hierarchic workflow to focus on specific targets based on analysis of metabolomics data and growth rescue experiments. We deploy this framework to understand the intracellular molecular interactions of the multi-valent dihydrofolate reductase-targeting antibiotic compound CD15-3. We analyse global metabolomics data utilizing machine learning, metabolic modelling, and protein structural similarity to prioritize candidate drug targets. Overexpression and in vitro activity assays confirm one of the predicted candidates, HPPK (folK), as a CD15-3 off-target. This study demonstrates how established machine learning methods can be combined with mechanistic analyses to improve the resolution of drug target finding workflows for discovering off-targets of a metabolic inhibitor.
format Online
Article
Text
id pubmed-10256842
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-102568422023-06-11 Empowering drug off-target discovery with metabolic and structural analysis Chowdhury, Sourav Zielinski, Daniel C. Dalldorf, Christopher Rodrigues, Joao V. Palsson, Bernhard O. Shakhnovich, Eugene I. Nat Commun Article Elucidating intracellular drug targets is a difficult problem. While machine learning analysis of omics data has been a promising approach, going from large-scale trends to specific targets remains a challenge. Here, we develop a hierarchic workflow to focus on specific targets based on analysis of metabolomics data and growth rescue experiments. We deploy this framework to understand the intracellular molecular interactions of the multi-valent dihydrofolate reductase-targeting antibiotic compound CD15-3. We analyse global metabolomics data utilizing machine learning, metabolic modelling, and protein structural similarity to prioritize candidate drug targets. Overexpression and in vitro activity assays confirm one of the predicted candidates, HPPK (folK), as a CD15-3 off-target. This study demonstrates how established machine learning methods can be combined with mechanistic analyses to improve the resolution of drug target finding workflows for discovering off-targets of a metabolic inhibitor. Nature Publishing Group UK 2023-06-09 /pmc/articles/PMC10256842/ /pubmed/37296102 http://dx.doi.org/10.1038/s41467-023-38859-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Chowdhury, Sourav
Zielinski, Daniel C.
Dalldorf, Christopher
Rodrigues, Joao V.
Palsson, Bernhard O.
Shakhnovich, Eugene I.
Empowering drug off-target discovery with metabolic and structural analysis
title Empowering drug off-target discovery with metabolic and structural analysis
title_full Empowering drug off-target discovery with metabolic and structural analysis
title_fullStr Empowering drug off-target discovery with metabolic and structural analysis
title_full_unstemmed Empowering drug off-target discovery with metabolic and structural analysis
title_short Empowering drug off-target discovery with metabolic and structural analysis
title_sort empowering drug off-target discovery with metabolic and structural analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256842/
https://www.ncbi.nlm.nih.gov/pubmed/37296102
http://dx.doi.org/10.1038/s41467-023-38859-x
work_keys_str_mv AT chowdhurysourav empoweringdrugofftargetdiscoverywithmetabolicandstructuralanalysis
AT zielinskidanielc empoweringdrugofftargetdiscoverywithmetabolicandstructuralanalysis
AT dalldorfchristopher empoweringdrugofftargetdiscoverywithmetabolicandstructuralanalysis
AT rodriguesjoaov empoweringdrugofftargetdiscoverywithmetabolicandstructuralanalysis
AT palssonbernhardo empoweringdrugofftargetdiscoverywithmetabolicandstructuralanalysis
AT shakhnovicheugenei empoweringdrugofftargetdiscoverywithmetabolicandstructuralanalysis